Format

Send to

Choose Destination
Eur J Pharm Sci. 2017 Jan 1;96:598-609. doi: 10.1016/j.ejps.2016.09.027. Epub 2016 Sep 23.

IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds.

Author information

1
University of Manchester, United Kingdom. Electronic address: alison.margolskee@manchester.ac.uk.
2
University of Manchester, United Kingdom.
3
AstraZeneca, United Kingdom; Sanofi, France.
4
Simcyp Ltd., United Kingdom.
5
Simulations Plus, Inc., United States.
6
University of Manchester, United Kingdom; Simcyp Ltd., United Kingdom.
7
AbbVie, Germany.
8
AstraZeneca, Sweden.
9
AstraZeneca, United States.
10
AstraZeneca, United Kingdom.
11
Bayer Pharma AG, Germany.
12
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
13
GlaxoSmithKline, United Kingdom.
14
Janssen, Belgium.
15
Novartis, Switzerland.
16
Pfizer, United Kingdom.
17
Sanofi, United States.
18
Sanofi, France.
19
Sanofi, Germany.
20
Uppsala University, Sweden.

Abstract

Predicting oral bioavailability (Foral) is of importance for estimating systemic exposure of orally administered drugs. Physiologically-based pharmacokinetic (PBPK) modelling and simulation have been applied extensively in biopharmaceutics recently. The Oral Biopharmaceutical Tools (OrBiTo) project (Innovative Medicines Initiative) aims to develop and improve upon biopharmaceutical tools, including PBPK absorption models. A large-scale evaluation of PBPK models may be considered the first step. Here we characterise the OrBiTo active pharmaceutical ingredient (API) database for use in a large-scale simulation study. The OrBiTo database comprised 83 APIs and 1475 study arms. The database displayed a median logP of 3.60 (2.40-4.58), human blood-to-plasma ratio of 0.62 (0.57-0.71), and fraction unbound in plasma of 0.05 (0.01-0.17). The database mainly consisted of basic compounds (48.19%) and Biopharmaceutics Classification System class II compounds (55.81%). Median human intravenous clearance was 16.9L/h (interquartile range: 11.6-43.6L/h; n=23), volume of distribution was 80.8L (54.5-239L; n=23). The majority of oral formulations were immediate release (IR: 87.6%). Human Foral displayed a median of 0.415 (0.203-0.724; n=22) for IR formulations. The OrBiTo database was found to be largely representative of previously published datasets. 43 of the APIs were found to satisfy the minimum inclusion criteria for the simulation exercise, and many of these have significant gaps of other key parameters, which could potentially impact the interpretability of the simulation outcome. However, the OrBiTo simulation exercise represents a unique opportunity to perform a large-scale evaluation of the PBPK approach to predicting oral biopharmaceutics.

KEYWORDS:

Absorption; Biopharmaceutics; Drug database; Modelling and simulation (M&S); Oral bioavailability (F(oral)); Physiologically-based pharmacokinetics (PBPK)

PMID:
27671970
DOI:
10.1016/j.ejps.2016.09.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center